Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04806347 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
Interventions: CliniMACS® System (Device), TCRαβ+/CD19+ depleted Hematopoietic stem cell (HSC) graft (Biological) to CliniMACS® System (Device), TCRαβ+/CD19+ depleted Hematopoietic stem cell (HSC) graft (Biological)
Eligibility criteria expanded, about 47 words
Secondary endpoints: details revised at 5 of 15 entries
MinorStart date: Aug 2026 to Sep 2026v40
MinorPrimary completion pushed from May 2029 to Jun 2029
Study completion pushed from May 2030 to Jun 2030
Start date: Jul 2026 to Aug 2026
v39
MinorStart date: Jun 2026 to Jul 2026v38
Show 36 earlier versionsHide 36 earlier versions
NotableStart date: Apr 2026 to Jun 2026v37Show 4 more changesShow less
Eligibility criteria expanded, about 35 words
Secondary endpoints revised (15)
Primary endpoints revised (4)
Study description expanded, about 308 words
MinorRe-verified, no change to tracked fieldsv36
NotableStart date: Jan 2026 to Apr 2026
Primary completion date: Feb 2029 to May 2029
Study completion date: Feb 2030 to May 2030
v35
NotableStart date: Nov 2025 to Jan 2026
Primary completion date: Dec 2028 to Feb 2029
Study completion date: Dec 2029 to Feb 2030
v34
NotableStart date: Sep 2025 to Nov 2025v33
NotableStart date: Jul 2025 to Sep 2025
Primary completion date: Oct 2028 to Dec 2028
Study completion date: Oct 2029 to Dec 2029
v32
NotableStart date: Apr 2025 to Jul 2025
Primary completion date: Jul 2028 to Oct 2028
Study completion date: Jul 2029 to Oct 2029
v31
NotableStart date: Jan 2025 to Apr 2025v30
NotableStart date: Nov 2024 to Jan 2025
Primary completion date: May 2028 to Jul 2028
Study completion date: May 2029 to Jul 2029
v29
NotableStart date: Aug 2024 to Nov 2024v28
NotableStart date: Jun 2024 to Aug 2024
Primary completion date: Mar 2028 to May 2028
Study completion date: Mar 2029 to May 2029
v27
NotableStart date: Mar 2024 to Jun 2024v26
NotableStart date: Dec 2023 to Mar 2024v25
NotableStart date: Oct 2023 to Dec 2023v24
MinorStart date: Sep 2023 to Oct 2023v23
MinorStart date: Aug 2023 to Sep 2023v22
MinorStart date: Jul 2023 to Aug 2023v21
MinorStart date: Jun 2023 to Jul 2023v20
MinorStart date: May 2023 to Jun 2023v19
MinorStart date: Apr 2023 to May 2023v18
NotablePrimary completion date: May 2026 to Mar 2028
Study completion date: May 2027 to Mar 2029
Start date: Mar 2023 to Apr 2023
v17
MinorRe-verified, no change to tracked fieldsv16
NotableStart date: Dec 2022 to Mar 2023
Primary completion date: Feb 2026 to May 2026
Study completion date: Feb 2027 to May 2027
v15
NotableStart date: Oct 2022 to Dec 2022v14
NotableStart date: Aug 2022 to Oct 2022v13
MinorStart date: Jul 2022 to Aug 2022v12
MinorStart date: Jun 2022 to Jul 2022v11
NotableStart date: Apr 2022 to Jun 2022v10
MinorStart date: Mar 2022 to Apr 2022v9
NotableStart date: Dec 2021 to Mar 2022v8
NotableStart date: Oct 2021 to Dec 2021v7
NotableStart date: Aug 2021 to Oct 2021v6
MinorStart date: Jul 2021 to Aug 2021v5
MinorStart date: Jun 2021 to Jul 2021v4
MinorStart date: May 2021 to Jun 2021v3
MinorStart date: Apr 2021 to May 2021v2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is being done to see if the investigators can take peripheral blood stem cells from either an adult family member or a closely matched unrelated donor, and run them through a special lab instrument to remove alpha/beta T cells and B cells and then give them to the patient to treat disease. This is an experimental way of doing a hematopoietic stem cell transplant (HSCT). The investigators want to see if the new stem cells will grow without bad graft vs. host disease (GVHD). This treatment approach is experimental in the United States.